[go: up one dir, main page]

MA40281B1 - Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t - Google Patents

Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t

Info

Publication number
MA40281B1
MA40281B1 MA40281A MA40281A MA40281B1 MA 40281 B1 MA40281 B1 MA 40281B1 MA 40281 A MA40281 A MA 40281A MA 40281 A MA40281 A MA 40281A MA 40281 B1 MA40281 B1 MA 40281B1
Authority
MA
Morocco
Prior art keywords
type
calcium channel
blocking agents
channel blocking
pyrazole compounds
Prior art date
Application number
MA40281A
Other languages
English (en)
Other versions
MA40281A (fr
Inventor
Bibia Heidmann
Simon Stamm
Romain Siegrist
John Gatfield
Olivier Bezencon
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA40281A publication Critical patent/MA40281A/fr
Publication of MA40281B1 publication Critical patent/MA40281B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (i) formule (i) dans laquelle x, y, r1, r2, (r4)n, et (r5)m sont tels que définis dans la description, et des sels pharmaceutiquement acceptables de ces composés. Ces composés sont utiles en tant que bloqueurs des canaux calciques de type t
MA40281A 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t MA40281B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2014061901 2014-06-03
EP15728640.2A EP3152199B1 (fr) 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
PCT/IB2015/054164 WO2015186056A1 (fr) 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant que bloqueurs des canaux calciques de type t

Publications (2)

Publication Number Publication Date
MA40281A MA40281A (fr) 2015-12-10
MA40281B1 true MA40281B1 (fr) 2018-11-30

Family

ID=53385705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40281A MA40281B1 (fr) 2014-06-03 2015-06-02 Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t

Country Status (33)

Country Link
US (2) US9932314B2 (fr)
EP (1) EP3152199B1 (fr)
JP (1) JP6195684B2 (fr)
KR (1) KR101906031B1 (fr)
CN (1) CN106414429B (fr)
AR (1) AR100712A1 (fr)
AU (1) AU2015270118C1 (fr)
CA (1) CA2947002C (fr)
CL (1) CL2016003092A1 (fr)
CY (1) CY1120864T1 (fr)
DK (1) DK3152199T3 (fr)
EA (1) EA031104B1 (fr)
ES (1) ES2696351T3 (fr)
HR (1) HRP20181670T1 (fr)
HU (1) HUE040489T2 (fr)
IL (1) IL249275B (fr)
LT (1) LT3152199T (fr)
MA (1) MA40281B1 (fr)
MX (1) MX376481B (fr)
NZ (1) NZ727818A (fr)
PE (1) PE20170129A1 (fr)
PH (1) PH12016502230B1 (fr)
PL (1) PL3152199T3 (fr)
PT (1) PT3152199T (fr)
RS (1) RS57943B1 (fr)
SG (1) SG11201609974PA (fr)
SI (1) SI3152199T1 (fr)
TN (1) TN2016000542A1 (fr)
TR (1) TR201816624T4 (fr)
TW (2) TWI690513B (fr)
UA (1) UA121548C2 (fr)
WO (1) WO2015186056A1 (fr)
ZA (1) ZA201608821B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6195684B2 (ja) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
PL3194374T3 (pl) 2014-09-15 2019-01-31 Idorsia Pharmaceuticals Ltd Związki triazolowe jako blokery kanału wapniowego typu t
MX2018009633A (es) * 2016-02-09 2018-12-17 Inventisbio Inc Inhibidor de indoleamina-2,3-dioxigenasa (ido).
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
WO2018109152A1 (fr) 2016-12-16 2018-06-21 Idorsia Pharmaceuticals Ltd Combinaison pharmaceutique comprenant un bloqueur de canal calcique de type t
US20210128537A1 (en) * 2016-12-21 2021-05-06 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
WO2018141961A1 (fr) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
UA126582C2 (uk) * 2017-07-05 2022-11-02 Ідорсія Фармасьютікалз Лтд Кристалічна форма n-[1-(5-ціанопіридин-2-ілметил)-1h-піразол-3-іл]-2-[4-(1-трифторметилциклопропіл)-феніл]-ацетаміду
WO2019113693A1 (fr) * 2017-12-12 2019-06-20 Queen's University At Kingston Composés et procédés d'inhibition d'enzymes cyp26
WO2021007478A1 (fr) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Composés de sulfone et leurs compositions pharmaceutiques, et leurs applications thérapeutiques pour le traitement de maladies neurodégénératives
US12528772B2 (en) 2019-07-11 2026-01-20 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
JP2023507430A (ja) * 2019-12-20 2023-02-22 イドルシア ファーマスーティカルズ リミテッド Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセトアミドを含む薬学的組成物
EP4229037A2 (fr) * 2020-10-16 2023-08-23 CeMM - Forschungszentrum für Molekulare Medizin GmbH Composés d'ubiquitine ligase cullin ring et utilisations associées
EP4349809A4 (fr) * 2021-07-02 2024-10-09 Lg Chem, Ltd. Procédé de préparation d'un intermédiaire pour la synthèse d'un inhibiteur de la xanthine oxydase
WO2023240205A1 (fr) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Composés deutérés
TW202509022A (zh) * 2023-07-10 2025-03-01 南韓商Ｌｇ化學股份有限公司 製備用於合成黃嘌呤氧化酶抑制劑之中間體之方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526790T2 (de) 1994-06-24 2003-03-06 Euroceltique S.A., Luxemburg/Luxembourg Verbindungen zur hemmung von phosphodiesrerase iv
EP0946508B1 (fr) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company COMPOSES HETEROAROMATIQUES CONTENANT DE L'AZOTE, UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
WO2002053101A2 (fr) 2000-12-29 2002-07-11 Alteon, Inc. Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
EP1353674A1 (fr) 2000-12-29 2003-10-22 Alteon, Inc. Methode de traitement du glaucome ivb
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7105548B2 (en) 2001-12-18 2006-09-12 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
JP2006522164A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のジアリール置換ピラゾール修飾因子
CN100537564C (zh) 2003-04-04 2009-09-09 麦克公司 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1620405A2 (fr) * 2003-05-01 2006-02-01 Abbott Laboratories Pyrazole-amides et sulfonamides modulateurs des canaux sodiques
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
GEP20094751B (en) 2004-08-18 2009-08-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
JP2008525363A (ja) 2004-12-23 2008-07-17 グラクソ グループ リミテッド プロスタグランジン媒介疾患治療のためのピリジン化合物
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
FR2889234B1 (fr) * 2005-07-27 2007-11-23 Andre Prieur Arret de porte a positions de maintien indeterminees
KR100654328B1 (ko) * 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
CA2634147A1 (fr) 2005-12-22 2007-06-28 Icagen, Inc. Antagonistes des canaux calciques
DK2010493T3 (en) * 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
MX2009000688A (es) * 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EP2117577A1 (fr) 2007-01-05 2009-11-18 Arena Pharmaceuticals, Inc. Récepteur couplé aux protéines g et modulateur dudit récepteur pour le traitement de troubles neurologiques liés au gaba et notamment de troubles liés au sommeil
EP2166846B1 (fr) 2007-06-20 2012-10-17 Merck Sharp & Dohme Corp. Inhibiteurs des janus kinases
ES2446932T3 (es) * 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina
CA2703471A1 (fr) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t a base d'amide de pyrazinyle
EP2212293A4 (fr) 2007-10-24 2010-12-01 Merck Sharp & Dohme Antagonistes des canaux calciques de type t à base d'amide hétérocyclique
BRPI0818244A2 (pt) 2007-10-24 2015-06-16 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
WO2009118596A2 (fr) * 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Dérivés de phtalimide en tant que modulateurs de trpa1
AU2009231258A1 (en) 2008-04-04 2009-10-08 Biomarin Iga Limited Compounds for treating muscular dystrophy
WO2010004390A1 (fr) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Dérivés de quinazoline dione en tant que modulateurs de trpa1
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
WO2010073011A2 (fr) 2008-12-23 2010-07-01 Betagenon Ab Composés utiles comme médicaments
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
CA2749893A1 (fr) 2009-02-04 2010-08-12 Pfizer Inc. Derives de 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one
WO2010122088A1 (fr) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole et triazole carboxamides en tant qu'inhibiteurs du canal crac
UY32571A (es) 2009-04-24 2010-11-30 Glaxo Group Ltd Compuestos derivados de pirazol amida
US8476294B2 (en) 2009-06-04 2013-07-02 Novartis Ag 1H-imidazo[4,5-c]quinolinone derivatives
WO2011022315A1 (fr) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Antagonistes de canal calcium de type t de pyrazinylphénylamide
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
WO2011053542A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t amides hétérocycliques
CA2782885A1 (fr) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase
WO2011093352A1 (fr) 2010-01-27 2011-08-04 武田薬品工業株式会社 Dérivé de thiazole
EP2402327B1 (fr) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Composés d'acétamide en tant qu'activateurs de la glucokinase, leur procédé et applications médicales
US8580829B2 (en) 2010-08-26 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR101593288B1 (ko) 2011-03-07 2016-02-11 화이자 인코포레이티드 항균제로서 유용한 플루오로-피리디논 유도체
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2991994B1 (fr) * 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Inhibiteurs du ror-gamma à base de thiazolopyrrolidine
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
EP2848615A1 (fr) * 2013-07-03 2015-03-18 Almirall, S.A. Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
JP6195684B2 (ja) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
PL3194374T3 (pl) 2014-09-15 2019-01-31 Idorsia Pharmaceuticals Ltd Związki triazolowe jako blokery kanału wapniowego typu t
EP3250563B1 (fr) 2015-01-30 2022-01-12 Neurocrine Biosciences, Inc. Triazoles substitués et procédés associés
CA2978007A1 (fr) * 2015-02-27 2016-09-01 Calcimedica, Inc. Traitement de la pancreatite

Also Published As

Publication number Publication date
SG11201609974PA (en) 2016-12-29
PH12016502230A1 (en) 2017-01-09
ZA201608821B (en) 2019-05-29
CA2947002C (fr) 2023-01-03
JP6195684B2 (ja) 2017-09-13
MA40281A (fr) 2015-12-10
EP3152199B1 (fr) 2018-08-15
TWI690513B (zh) 2020-04-11
RS57943B1 (sr) 2019-01-31
KR101906031B1 (ko) 2018-10-08
LT3152199T (lt) 2018-11-12
SI3152199T1 (sl) 2018-12-31
KR20170012432A (ko) 2017-02-02
BR112016028315A8 (pt) 2017-12-26
JP2017516830A (ja) 2017-06-22
NZ727818A (en) 2020-06-26
AU2015270118C1 (en) 2019-11-28
IL249275B (en) 2020-01-30
US9932314B2 (en) 2018-04-03
TW201930270A (zh) 2019-08-01
MX2016015923A (es) 2017-02-27
AU2015270118A1 (en) 2017-01-12
HUE040489T2 (hu) 2019-03-28
UA121548C2 (uk) 2020-06-25
CL2016003092A1 (es) 2017-05-12
EA201692521A1 (ru) 2017-05-31
PH12016502230B1 (en) 2019-11-06
TWI675827B (zh) 2019-11-01
MX376481B (es) 2025-03-07
CN106414429B (zh) 2020-01-03
TN2016000542A1 (en) 2018-04-04
US20180105496A1 (en) 2018-04-19
TR201816624T4 (tr) 2018-11-21
PL3152199T3 (pl) 2019-01-31
BR112016028315A2 (pt) 2017-08-22
WO2015186056A1 (fr) 2015-12-10
IL249275A0 (en) 2017-02-28
ES2696351T3 (es) 2019-01-15
US10065929B2 (en) 2018-09-04
US20170096399A1 (en) 2017-04-06
CN106414429A (zh) 2017-02-15
PE20170129A1 (es) 2017-03-30
CY1120864T1 (el) 2019-12-11
EP3152199A1 (fr) 2017-04-12
AU2015270118B2 (en) 2019-09-12
CA2947002A1 (fr) 2015-12-10
HRP20181670T1 (hr) 2018-12-14
EA031104B1 (ru) 2018-11-30
TW201625551A (zh) 2016-07-16
DK3152199T3 (en) 2018-11-26
PT3152199T (pt) 2018-11-26
AR100712A1 (es) 2016-10-26

Similar Documents

Publication Publication Date Title
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
MX2018010191A (es) Inhibidores de glucosidasa.
MX2017002670A (es) Inhibidores de glucosidasa.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
MX2015016495A (es) Compuestos de 3,4-dihidroisoquinolin-2 (1h)-ilo.
BR112017006251A2 (pt) novos compostos
MA40302A1 (fr) Dérivés de carbazole
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MX390051B (es) Antagonistas de ep4.
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
JO3742B1 (ar) مركب بيرانو داي بيريدين
JOP20200030A1 (ar) مركب خماسي الحلقة
CL2015002188A1 (es) Agentes analgésicos oculares tópicos